Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

24.480
+0.7203.03%
Volume:- -
Turnover:- -
Market Cap:21.35B
PE:71.39
High:24.480
Open:24.480
Low:24.480
Close:23.760
52wk High:30.750
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:2.23
PE(LYR):71.39
PS:4.56

Loading ...

Hutchmed H1 Earnings Rise, Revenue Falls

MT Newswires Live
·
Aug 07

Earnings Flash (HCM) Hutchmed Posts H1 Earnings $2.61 Per ADS

MT Newswires Live
·
Aug 07

HUTCHMED (China) H1 EPS $2.65 Up From $0.15 YoY, Sales $277.677M Down From $305.681M YoY

Benzinga
·
Aug 07

HUTCHMED (China) - Updates FY25 Guidance for Oncology/Immunology CONSOL Revenue to $270 Mln - $350 Mln

THOMSON REUTERS
·
Aug 07

HUTCHMED Reports 2025 Interim Results

THOMSON REUTERS
·
Aug 07

Corrected-HUTCHMED (China) H1 Revenue USD 277.7 Million (Corrects Amount)

THOMSON REUTERS
·
Aug 07

HUTCHMED (China) Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

BOCOM International: Innovative Drug Sector's Recovery Prospects Remain Attractive; Focus on Commercial Insurance Drug Catalog Launch

Stock News
·
Jul 16

HUTCHMED (China) Ltd. Schedules Board Meeting to Approve and Announce 2025 Interim Results

Reuters
·
Jul 03

HUTCHMED to Announce 2025 Half-Year Financial Results

GlobeNewswire
·
Jul 03

Hutchmed New Drug Application for Lung Cancer Combination Treatment Approved in China

MT Newswires Live
·
Jun 30

BUZZ-HUTCHMED hits 2-month high on drug application for kidney cancer treatment

Reuters
·
Jun 05

HUTCHMED and Innovent Announce Regulatory Review Acceptance in China for Fruquintinib and Sintilimab Combination in Advanced Renal Cell Carcinoma Treatment

Reuters
·
Jun 05

BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab

Reuters
·
Jun 05

HK Movers | HK's Pharma Shares Soar. Hengrui Pharma Surges 29%; Asymchem up 7%; CSPC Pharma up 4%

Tiger Newspress
·
May 23